X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (472) 472
animals (295) 295
nitrophenols - pharmacology (256) 256
male (219) 219
nitrophenols - therapeutic use (200) 200
biphenyl compounds - pharmacology (185) 185
piperazines - pharmacology (181) 181
sulfonamides - pharmacology (180) 180
female (178) 178
apoptosis (170) 170
nitrophenols (140) 140
pharmacology & pharmacy (139) 139
apoptosis - drug effects (131) 131
cell line, tumor (131) 131
benzophenones - therapeutic use (125) 125
tolcapone (113) 113
oncology (112) 112
parkinson disease - drug therapy (112) 112
mice (111) 111
proto-oncogene proteins c-bcl-2 - antagonists & inhibitors (103) 103
proteins (98) 98
proto-oncogene proteins c-bcl-2 - metabolism (96) 96
catechol o-methyltransferase inhibitors (94) 94
rats (92) 92
cancer (89) 89
antiparkinson agents - therapeutic use (87) 87
abt-737 (78) 78
antineoplastic agents - pharmacology (77) 77
middle aged (77) 77
aged (73) 73
drug synergism (73) 73
cell biology (70) 70
biphenyl compounds - therapeutic use (66) 66
expression (65) 65
levodopa - therapeutic use (62) 62
benzophenones - pharmacology (61) 61
nanoparticles (61) 61
chemistry, multidisciplinary (60) 60
piperazines - therapeutic use (59) 59
sulfonamides - therapeutic use (59) 59
bcl-2 (58) 58
clinical neurology (58) 58
nitrophenol (58) 58
dose-response relationship, drug (57) 57
levodopa (57) 57
chemotherapy (56) 56
mcl-1 (56) 56
toxicology (55) 55
nitrophenols - metabolism (54) 54
bh3 mimetic abt-737 (53) 53
adult (51) 51
analysis (51) 51
biochemistry & molecular biology (51) 51
parkinson's disease (51) 51
activation (50) 50
p-nitrophenol (50) 50
enzyme inhibitors - therapeutic use (49) 49
research (49) 49
nitrophenols - chemistry (47) 47
drug therapy, combination (46) 46
resistance (46) 46
benzophenones - adverse effects (45) 45
enzyme inhibitors - pharmacology (45) 45
pharmacokinetics (45) 45
leukemia (44) 44
catalysis (43) 43
cell survival - drug effects (43) 43
proto-oncogene proteins c-bcl-2 - genetics (43) 43
in-vitro (41) 41
double-blind (40) 40
kinetics (40) 40
metabolism (40) 40
catechols - therapeutic use (39) 39
research article (39) 39
nanoscience & nanotechnology (38) 38
neurosciences (38) 38
nitrophenols - administration & dosage (37) 37
gene expression (36) 36
materials science, multidisciplinary (36) 36
nanotechnology (36) 36
treatment outcome (36) 36
antineoplastic agents - therapeutic use (35) 35
catechol-o-methyltransferase (35) 35
inhibition (35) 35
inhibitor (35) 35
myeloid cell leukemia sequence 1 protein (35) 35
antiparkinson agents - adverse effects (34) 34
nitriles (34) 34
organophosphorus compounds - therapeutic use (34) 34
xenograft model antitumor assays (34) 34
health aspects (33) 33
dihydropyridines - therapeutic use (32) 32
entacapone (32) 32
enzymes (32) 32
hematology (32) 32
time factors (32) 32
biology (31) 31
medicine (31) 31
drug therapy (30) 30
gold (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (713) 713
German (13) 13
French (11) 11
Spanish (10) 10
Japanese (7) 7
Russian (6) 6
Czech (5) 5
Chinese (4) 4
Portuguese (3) 3
Dutch (2) 2
Hungarian (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Movement disorders, ISSN 1531-8257, 2005, Volume 20, Issue 5, pp. 523 - 539
The objective of this study is to update a previous evidence‐based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January... 
evidence‐based medicine | Parkinson's disease | levodopa | monoamine oxidase inhibitors | COMT inhibitors | amantadine | neurosurgery | dopamine agonists | anticholinergics | deep brain stimulation | neurotransplantation | Anticholinergics | Amantadine | Monoamine oxidase inhibitors | Deep brain stimulation | Dopamine agonist | Neurotransplantation | Levodopa | Neurosurgery | Evidence-based medicine | CONTROLLED-TRIAL | SUBTHALAMIC NUCLEUS STIMULATION | DAYTIME SLEEPINESS | dopan-tine agonists | RANDOMIZED-TRIAL | INITIAL TREATMENT | COGNITIVE FUNCTION | CLINICAL NEUROLOGY | EMBRYONIC DOPAMINE NEURONS | MOTOR FLUCTUATIONS | DOUBLE-BLIND | evidence-based medicine | Mesencephalon - cytology | Humans | Parkinson Disease - drug therapy | Piribedil - therapeutic use | Apomorphine - therapeutic use | Thiazoles - therapeutic use | Amantadine - therapeutic use | Indans - therapeutic use | Bromocriptine - therapeutic use | Antiparkinson Agents - therapeutic use | Lisuride - therapeutic use | Nitrophenols - therapeutic use | Fetal Tissue Transplantation - methods | Selegiline - therapeutic use | Monoamine Oxidase Inhibitors - therapeutic use | Benzophenones - therapeutic use | Levodopa - therapeutic use | Pergolide - therapeutic use | Deep Brain Stimulation - methods | Ergolines - therapeutic use | Parkinson Disease - surgery | Mesencephalon - embryology | Globus Pallidus - surgery | Indoles - therapeutic use | Catechol O-Methyltransferase Inhibitors | Neurosurgical Procedures - methods | Dihydroergocryptine - therapeutic use | Benzothiazoles
Journal Article
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2017, Volume 140, Issue 2, pp. 418 - 430
.... Corticosteroid-resistant neutrophilic asthma remains mechanistically poorly understood and requires novel effective therapeutic strategies... 
Allergy and Immunology | Bcl-2 | apoptosis | steroid insensitive | Airway inflammation | eosinophil | neutrophil | SURVIVAL | MANAGEMENT | SPUTUM | IMMUNOLOGY | CELL-DEATH | FAMILY | ALLERGY | ASTHMA | GLUCOCORTICOID RESISTANCE | MOLECULAR-MECHANISMS | Asthma - metabolism | Eosinophils - drug effects | Ovalbumin - immunology | Apoptosis - drug effects | Humans | Male | Adrenal Cortex Hormones - therapeutic use | Biphenyl Compounds - therapeutic use | Eosinophils - immunology | Freund's Adjuvant - immunology | Alum Compounds | Proto-Oncogene Proteins c-bcl-2 - metabolism | Dexamethasone - pharmacology | Allergens - immunology | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Nitrophenols - therapeutic use | Asthma - immunology | Anti-Inflammatory Agents - therapeutic use | Bronchoalveolar Lavage Fluid - cytology | Lung - metabolism | Anti-Inflammatory Agents - pharmacology | Mice, Inbred C57BL | Neutrophils - drug effects | Neutrophils - immunology | Adrenal Cortex Hormones - pharmacology | Mice, Transgenic | Drug Resistance - drug effects | Piperazines - therapeutic use | Sulfonamides - pharmacology | Asthma - drug therapy | Piperazines - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Dexamethasone - therapeutic use | Animals | Sulfonamides - therapeutic use | Lung - drug effects | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Proto-Oncogene Proteins c-bcl-2 - genetics | Yuan (China) | Medical research | Medical colleges | Corticosteroids | Medicine, Experimental | Inflammation | Health aspects | Asthma | Dendritic cells | Analysis | Health care | Drugs | Corticoids | Allergens | Animal models | Bcl-2 protein | Immune clearance | Helper cells | Lymphocytes T | Inflammatory diseases | Immunosuppressive agents | Respiratory tract | Transgenic animals | Bronchoalveolar lavage | Rodents | Respiratory tract diseases | Alveoli | Public health | Immune system | Leukocytes (eosinophilic) | Neutrophils | Transgenic mice | Bronchus | Leukocytes (neutrophilic) | FDA approval | Disease control | Allergies | Hemopoiesis | Studies | Inhibitors | Mice | Leukocytes (granulocytic) | Steroid hormones | Steroids | Apoptosis | Eosinophils
Journal Article
International journal of oncology, ISSN 1019-6439, 09/2018, Volume 53, Issue 3, pp. 1055 - 1068
The poor prognosis and high mortality of patients with ovarian cancer result in part from their poor response to platinum-based chemotherapy. However, the... 
Reactive oxygen species | Cisplatin resistance | Cancer metabolism | Oxidative phosphorylation | Ovarian cancer cells | Bcl-2 family | OXIDATIVE-PHOSPHORYLATION | MITOCHONDRIA METABOLISM | APOPTOSIS | cisplatin resistance | BCL-2 FAMILY PROTEINS | TUMOR-CELLS | DRUG-RESISTANCE | oxidative phosphorylation | cancer metabolism | GLUCOSE-6-PHOSPHATE-DEHYDROGENASE | ovarian cancer cells | INHIBITION | ONCOLOGY | reactive oxygen species | MULTIDRUG-RESISTANCE | MODULATION | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Humans | Ovarian Neoplasms - pathology | Antimetabolites - therapeutic use | Biphenyl Compounds - therapeutic use | Glycolysis - drug effects | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Deoxyglucose - therapeutic use | Oxidative Phosphorylation - drug effects | Proto-Oncogene Proteins c-bcl-2 - metabolism | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Deoxyglucose - pharmacology | Nitrophenols - therapeutic use | Female | Ovarian Neoplasms - drug therapy | Antimetabolites - pharmacology | Cell Survival - drug effects | Mitochondria - metabolism | Piperazines - therapeutic use | Cisplatin - pharmacology | Mitochondria - drug effects | Sulfonamides - pharmacology | Piperazines - pharmacology | Drug Synergism | Cisplatin - therapeutic use | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Line, Tumor | Glucose - metabolism | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Cell Proliferation - drug effects | Drug Resistance, Neoplasm - drug effects
Journal Article
Oncogene, ISSN 1476-5594, 2009, Volume 27, Issue S1, pp. S149 - S157
Cancer cells show deviant behavior that induces apoptotic signaling. To survive, cancer cells typically acquire changes enabling evasion of death signals. One... 
Bcl-2 | Drug resistance and ABT-737 | BH3 mimetic | Apoptosis | Cancer | PROAPOPTOTIC ACTIVITY | BIOCHEMISTRY & MOLECULAR BIOLOGY | MIMETIC ABT-737 | BCL-2 FAMILY PROTEINS | apoptosis | OUTER MITOCHONDRIAL-MEMBRANE | ANTIAPOPTOTIC BCL-2 | SMALL-MOLECULE INHIBITOR | CELL BIOLOGY | CYTOCHROME-C | SURVIVAL-PROMOTING PROTEINS | ONCOLOGY | X-L | GENETICS & HEREDITY | CHRONIC LYMPHOCYTIC-LEUKEMIA | cancer | drug resistance and ABT-737 | Neoplasms - metabolism | Sulfones - therapeutic use | Multigene Family | Proto-Oncogene Proteins c-bcl-2 - physiology | Apoptosis - drug effects | Humans | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Piperazines - chemistry | Structure-Activity Relationship | Nitrophenols - chemistry | Drug Delivery Systems | Benzamides - therapeutic use | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | Thionucleotides - chemistry | Sulfones - chemistry | Drug Design | Proto-Oncogene Proteins c-bcl-2 - chemistry | Antineoplastic Agents - pharmacology | Biphenyl Compounds - chemistry | Antineoplastic Agents - classification | Pyrroles - therapeutic use | Dimerization | Benzamides - chemistry | Binding, Competitive | Protein Structure, Tertiary | Sulfonamides - chemistry | Thionucleotides - therapeutic use | Clinical Trials as Topic | Mitochondria - drug effects | Antineoplastic Agents - chemistry | Sulfonamides - pharmacology | Piperazines - pharmacology | Neoplasms - drug therapy | Animals | Sulfonamides - therapeutic use | Pyrroles - chemistry | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Mice | Aniline Compounds - chemistry | Aniline Compounds - therapeutic use | Mitochondria - physiology | Drug Screening Assays, Antitumor | Proteins | Signal transduction | Oncology | Molecular biology
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 03/2015, Volume 125, Issue 3, pp. 1081 - 1097
... cancer in this age group (1-3). T cell ALL (T-ALL) represents 10%-15% of ALL cases in children and 25% of adult T-ALL cases. The use of conventional cancer therapies... 
MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATION | SIGNALING PATHWAY | INDUCED APOPTOSIS | TOLL-LIKE RECEPTOR | KINASE | INNATE IMMUNE-SYSTEM | INTERLEUKIN-1 RECEPTOR | ANTITUMOR-ACTIVITY | EXPRESSION | MYD88 | Vincristine - pharmacology | Humans | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | Antineoplastic Agents - therapeutic use | Biphenyl Compounds - therapeutic use | Biphenyl Compounds - pharmacology | MCF-7 Cells | Nitrophenols - pharmacology | Nitrophenols - therapeutic use | HEK293 Cells | Female | Antineoplastic Agents - pharmacology | Protein Stability | Benzimidazoles - therapeutic use | Cell Survival - drug effects | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Jurkat Cells | Mice, Inbred C57BL | Piperazines - therapeutic use | Mice, SCID | Sulfonamides - pharmacology | Piperazines - pharmacology | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Interleukin-1 Receptor-Associated Kinases - antagonists & inhibitors | TNF Receptor-Associated Factor 6 - metabolism | Vincristine - therapeutic use | Benzimidazoles - pharmacology | Mice, Inbred NOD | Cell Proliferation - drug effects | Antimitotic agents | Medical research | Chemotherapy | Physiological aspects | Medicine, Experimental | Research | Acute lymphocytic leukemia | Antineoplastic agents | T cells | Cancer | Flow cytometry | Phosphorylation | Leukemia | Values | Kinases | Experiments | Cancer therapies | Patients | Studies | Lymphocytes | Rodents | Medical prognosis | Adapter proteins | Tumors
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2011, Volume 109, Issue 8, pp. 2766 - 2771
Overexpression of the prosurvival protein BCL-2 is common in breast cancer. Here we have explored its role as a potential therapeutic target in this disease... 
Chemotherapy | Estrogens | Antineoplastics | BREAST CANCER SPECIAL FEATURE | Breast cancer | Breast neoplasms | Heterologous transplantation | Tumors | Cancer | Vehicles | Apoptosis | Programmed cell death | ABT-263 | Mammary | Navitoclax | Small molecule inhibitor | CANCER CELLS | SUBTYPES | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | CYTOTOXIC CHEMOTHERAPY | navitoclax | mammary | RESISTANCE | CHRONIC LYMPHOCYTIC-LEUKEMIA | PROGNOSTIC MARKER | programmed cell death | INHIBITOR | PROTEINS | BCL-2 FAMILY | small molecule inhibitor | Taxoids - pharmacology | Apoptosis - drug effects | Humans | Biphenyl Compounds - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Taxoids - therapeutic use | Bcl-2-Like Protein 11 | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | Nitrophenols - therapeutic use | Female | Membrane Proteins - metabolism | Breast Neoplasms - classification | Proto-Oncogene Proteins - metabolism | Piperazines - therapeutic use | Sulfonamides - pharmacology | Breast Neoplasms - drug therapy | Piperazines - pharmacology | Remission Induction | Apoptosis Regulatory Proteins - metabolism | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Myeloid Cell Leukemia Sequence 1 Protein | Cell Line, Tumor | Mice | bcl-X Protein - metabolism | Breast tumors | Physiological aspects | Development and progression | Genetic aspects | Research | Gene expression | Tumor proteins | Health aspects | Biological Sciences
Journal Article
Autophagy, ISSN 1554-8635, 2014, Volume 6, Issue 2, pp. 256 - 269
Apoptosis and autophagy have been shown to be negatively regulated by pro-survival Bcl-2 proteins. We determined whether the anti-cancer agent celecoxib, alone... 
Binding | Proteins | Landes | Calcium | Bioscience | Biology | Cell | Cycle | Cancer | Organogenesis | Bcl-2 | ABT-737 | Celecoxib | Autophagy | NSAID | Apoptosis | autophagy | celecoxib | apoptosis | DEATH | ENDOPLASMIC-RETICULUM STRESS | BH3 MIMETIC ABT-737 | CELL BIOLOGY | DRUG-INDUCED APOPTOSIS | SMALL-MOLECULE BCL-2 | PROTEINS | BCL-2 FAMILY-MEMBERS | GROWTH IN-VIVO | CYCLOOXYGENASE-2 INHIBITOR | ENZYME-INHIBITORS
Journal Article